Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FHCX9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,792
Award facts
- Contract value 100% obligated
- $15,792.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $15,792.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order, issued on November 18, 2025, with an ultimate completion date of December 10, 2025, was awarded without set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical support to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, holding a single-award IDC under PPV-G GEN V with a ceiling value of $499,999,999 through December 31, 2036. The company's extensive product portfolio spans branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, with recent delivery orders demonstrating substantial federal contracting activity across multiple therapeutic categories. As a prime vendor contractor under this major Department of Defense initiative, DMS Pharmaceutical Group supports recurring medical supply needs for military healthcare operations globally, with no identified subcontractor relationships in this award documentation.
Quick answers
Who was awarded contract SPE2DR26FHCX9?
SPE2DR26FHCX9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 18, 2025.
How much is contract SPE2DR26FHCX9 worth?
The government has obligated $15,792 on SPE2DR26FHCX9.
Is contract SPE2DR26FHCX9 an order under another contract?
Yes. SPE2DR26FHCX9 is a delivery order under SPE2DR25D9207, an indefinite delivery contract.
Was contract SPE2DR26FHCX9 competed?
The extent of competition for SPE2DR26FHCX9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award